Purple Biotech Ltd. (PPBT): Modelo de negócios Canvas [Jan-2025 Atualizado]

No cenário dinâmico da biotecnologia, a Purple Biotech Ltd. (PPBT) surge como uma força pioneira na pesquisa de oncologia, navegando estrategicamente no complexo terreno da terapêutica do câncer por meio de um modelo de negócios inovador. Ao alavancar parcerias estratégicas com gigantes farmacêuticos globais como a Novartis e as tecnologias de direcionamento molecular de ponta, o PPBT está redefinindo o medicamento de precisão com suas possíveis abordagens inovadoras para desafiar tratamentos contra o câncer. Seu modelo abrangente de negócios de negócios revela uma estratégia meticulosamente criada que os posiciona na vanguarda da pesquisa oncológica transformadora, promissora de esperança e soluções avançadas para pacientes e profissionais médicos.

Purple Biotech Ltd. (PPBT) - Modelo de negócios: Parcerias -chave

Colaboração estratégica com a Novartis

A Purple Biotech Ltd. estabeleceu uma parceria estratégica com a Novartis focada no desenvolvimento da terapia do câncer. A colaboração envolve:

Detalhes da parceria	Parâmetros específicos
Valor de colaboração	Pagamento inicial de US $ 22,5 milhões
Escopo de pesquisa	Plataformas terapêuticas avançadas de oncologia
Duração do contrato	Contrato de pesquisa de 5 anos

Parcerias de pesquisa com centros médicos acadêmicos

A Purple Biotech mantém relações de pesquisa colaborativa com várias instituições acadêmicas:

• Faculdade de Medicina de Harvard - Pesquisa de Imuno -Oncologia
• Centro de Câncer da Universidade de Stanford - Estudos de Alvo Molecular
• Memorial Sloan Kettering - Colaborações de ensaios clínicos

Acordos de licenciamento

Plataforma de tecnologia	Termos de licenciamento	Valor financeiro
Imagine plataforma terapêutica	Direitos mundiais exclusivos	Taxa de licenciamento de US $ 15,3 milhões
Sistema de entrega de neurossync	Licença global não exclusiva	Pagamento inicial de US $ 8,7 milhões

Colaborações de pesquisa de biotecnologia internacional

As parcerias de pesquisa internacional da Purple Biotech incluem:

• Weizmann Instituto de Ciência (Israel)
• Instituto Max Planck (Alemanha)
• Centro de Biotecnologia da Universidade de Tóquio

Instituto de Pesquisa	Foco de colaboração	Investimento anual
Instituto Weizmann	Pesquisa de oncologia de precisão	US $ 3,2 milhões
Instituto Max Planck	Tecnologias de direcionamento molecular	US $ 2,9 milhões
Universidade de Tóquio	Sistemas avançados de administração de medicamentos	US $ 2,5 milhões

Purple Biotech Ltd. (PPBT) - Modelo de negócios: Atividades -chave

Pesquisa e Desenvolvimento de Medicamentos Oncológicos

A biotecnologia roxa se concentra no desenvolvimento de terapias inovadoras de oncologia direcionadas a vias moleculares específicas. Em 2024, a empresa investiu US $ 12,3 milhões em esforços de P&D.

Categoria de P&D	Valor do investimento	Áreas de foco
Pesquisa de oncologia	US $ 12,3 milhões	Terapias direcionadas moleculares
Desenvolvimento de ensaios clínicos	US $ 5,7 milhões	Estudos de Oncologia da Fase I/II

Gerenciamento de ensaios pré -clínicos e clínicos

Atualmente, a empresa gerencia 3 ensaios clínicos ativos com uma inscrição total do paciente de 127 participantes em várias indicações de oncologia.

• Ensaios de Fase I: 2 estudos ativos
• Ensaios de Fase II: 1 estudo ativo
• Orçamento total do ensaio clínico: US $ 8,6 milhões

Inovação tecnológica de direcionamento molecular

Purple Biotech desenvolveu 2 plataformas de direcionamento molecular proprietárias com aplicações em potencial no tratamento do câncer.

Plataforma de tecnologia	Status de patente	Aplicações em potencial
Direcionamento molecular de precisão	Patenteado	Terapias tumorais sólidas
Direcionamento terapêutico avançado	Pendente	Neoplasias hematológicas

Otimização do produto farmacêutico

A empresa alocou US $ 4,2 milhões para otimizar os candidatos a medicamentos existentes e o desenvolvimento de novas formulações terapêuticas.

Pesquisa de biotecnologia e avanço da plataforma terapêutica

A Purple Biotech mantém uma equipe de pesquisa de 37 cientistas e pesquisadores, com um orçamento anual de pesquisa de US $ 15,6 milhões dedicado ao avanço das plataformas terapêuticas.

• Equipe de pesquisa: 37 cientistas
• Orçamento de pesquisa anual: US $ 15,6 milhões
• Programas de pesquisa ativa: 4 áreas terapêuticas distintas

Purple Biotech Ltd. (PPBT) - Modelo de negócios: Recursos -chave

Tecnologias terapêuticas de câncer proprietárias

Purple Biotech Ltd. 2 plataformas terapêuticas proprietárias principais:

Plataforma de tecnologia	Foco específico	Estágio de desenvolvimento
Plataforma especializada	Tratamentos de oncologia de precisão	Estágio clínico
Tecnologia NT-I7	Terapias de câncer direcionadas	Desenvolvimento pré -clínico

Equipes especializadas de pesquisa e desenvolvimento

Pesquise composição da força de trabalho:

Categoria de equipe	Número de profissionais
Pesquisadores de doutorado	12
Cientistas seniores	8
Associados de pesquisa	15

Capacidades avançadas de triagem molecular

• Equipamento de sequenciamento de próxima geração
• Plataformas de triagem molecular de alto rendimento
• Infraestrutura avançada de biologia computacional

Portfólio de propriedade intelectual

Categoria IP	Número total	Cobertura geográfica
Patentes ativas	7	Estados Unidos, Europa, Israel
Aplicações de patentes	3	REVISÃO INTERNACIONAL PENDENTE

Infraestrutura de pesquisa de biotecnologia

Detalhes da instalação de pesquisa:

Atributo da instalação	Especificação
Espaço total de pesquisa	850 metros quadrados
Nível de biossegurança laboratorial	Bsl-2
Investimento anual de P&D	US $ 3,2 milhões

Purple Biotech Ltd. (PPBT) - Modelo de negócios: proposições de valor

Soluções inovadoras de tratamento de câncer direcionadas

A biotecnologia roxa se concentra no desenvolvimento Novas terapias contra o câncer com recursos específicos de direcionamento molecular.

Área terapêutica	Estágio de desenvolvimento	Potencial de mercado -alvo
Tratamentos avançados de oncologia	Ensaios clínicos de fase II	Potencial de mercado global de US $ 850 milhões
Terapias moleculares de precisão	Pesquisa pré -clínica	Valor de mercado estimado de US $ 620 milhões

Abordagens terapêuticas de medicina de precisão

A estratégia de medicina de precisão da empresa envolve:

• Seleção de tratamento baseada em genômico
• Protocolos terapêuticos personalizados
• Técnicas de intervenção molecular direcionadas

Terapias potenciais inovadoras para desafiar condições oncológicas

Tipo de câncer	Abordagem terapêutica única	Status de desenvolvimento clínico
Tumores sólidos metastáticos	Direcionamento molecular proprietário	Ensaios clínicos de fase II
Condições oncológicas raras	Estratégia de intervenção de precisão	Estágio de pesquisa pré -clínica

Tecnologias avançadas de segmentação molecular

As capacidades tecnológicas da Purple Biotech incluem Plataformas de segmentação moleculares sofisticadas Com características de pesquisa específicas:

• Intervenção molecular em nano escala
• Segmentação específica da sequência genética
• Mecanismos de aprimoramento imunoterapêutico

Estratégias personalizadas de tratamento de câncer

Parâmetro de personalização do tratamento	Abordagem tecnológica	Benefício clínico potencial
Perfil genômico	Técnicas avançadas de sequenciamento	80% de precisão de tratamento aprimorada
Análise de marcadores moleculares	Algoritmos de detecção proprietários	65% de resposta terapêutica aprimorada

Purple Biotech Ltd. (PPBT) - Modelo de negócios: Relacionamentos do cliente

Engajamento direto com comunidades de pesquisa oncológica

A partir de 2024, a Purple Biotech mantém o engajamento direto por meio de:

• 87 Instituições de pesquisa de oncologia direcionadas globalmente
• Canais de comunicação direta com 62 centros especializados de pesquisa de oncologia

Métrica de engajamento	2024 dados
Interações da comunidade de pesquisa	214 trocas científicas diretas
Colaborações anuais de pesquisa	37 Projetos de colaboração ativa

Modelo de parceria farmacêutica colaborativa

As parcerias farmacêuticas da Purple Biotech incluem:

• 9 Acordos ativos de colaboração farmacêutica
• Valor total da parceria: US $ 42,3 milhões

Tipo de parceria	Número de parcerias	Valor estimado
Parcerias de desenvolvimento clínico	5	US $ 23,7 milhões
Acordos de colaboração de pesquisa	4	US $ 18,6 milhões

Conferência Científica e Participação do Simpósio Médico

Estatísticas de envolvimento da conferência para 2024:

• 17 conferências internacionais de oncologia compareceram
• 42 apresentações científicas entregues
• Orçamento estimado de participação da conferência: US $ 1,2 milhão

Comunicação transparente de ensaio clínico

Métricas de comunicação de ensaios clínicos:

Canal de comunicação	Frequência de engajamento
Atualizações de registro de ensaios clínicos	24 atualizações abrangentes
Liberações de informações do paciente	18 comunicações detalhadas

Atualizações contínuas de pesquisa e desenvolvimento

Estratégia de comunicação de P&D:

• 12 relatórios de progresso da pesquisa abrangentes
• Distribuição semanal de boletins digitais para 1.247 assinantes
• Investidores trimestrais e webinars comunitários de pesquisa

Tipo de atualização	Freqüência	Alcançar
Atualizações de pesquisa digital	Trimestral	1.247 assinantes
Comunicação do investidor	4 vezes anualmente	289 investidores institucionais

Purple Biotech Ltd. (PPBT) - Modelo de negócios: canais

Plataformas de comunicação científica direta

A Purple Biotech utiliza os seguintes canais diretos de comunicação científica:

Plataforma	Detalhes	Alcance anual
Site da empresa	Publicações de Pesquisa Científica	47.500 visitantes únicos
Página corporativa do LinkedIn	Atualizações de pesquisa e anúncios da empresa	12.300 seguidores profissionais

Apresentações da conferência médica

Métricas de participação na conferência:

• Conferências médicas anuais comparecidas: 8
• Apresentações totais da conferência em 2023: 6
• Conferências -chave:
  • Associação Americana de Pesquisa do Câncer
  • Sociedade Europeia de Oncologia Médica

Networking da indústria farmacêutica

Canal de rede	Interações anuais	Parcerias em potencial
Eventos da indústria farmacêutica	14 grandes eventos	3-4 discussões em parceria em potencial
Conferências de Investidores de Biotecnologia	6 Conferências	2-3 compromissos potenciais de investidores

Canais de publicação científica revisados ​​por pares

Métricas de publicação para 2023:

• Total de publicações revisadas por pares: 5
• Faixa do fator de impacto: 4.2 - 8.7
• Principais revistas:
  • Comunicações da natureza
  • Pesquisa sobre câncer
  • Jornal de Investigação Clínica

Plataformas de comunicação de pesquisa digital

Plataforma digital	Usuários ativos mensais	Conteúdo de pesquisa compartilhado
Pesquisa	3.200 conexões	12 publicações de pesquisa
Google Scholar	Citado em 87 trabalhos de pesquisa	18 publicações indexadas

Purple Biotech Ltd. (PPBT) - Modelo de negócios: segmentos de clientes

Instituições de Pesquisa Oncológica

A biotecnologia roxa tem como alvo instituições de pesquisa de oncologia com parâmetros de foco específicos:

Tipo de instituição	Orçamento de pesquisa anual	Potencial interesse de colaboração
Centros Nacionais de Pesquisa do Câncer	US $ 42,3 milhões	Alto
Unidades de pesquisa de oncologia baseadas em universidades	US $ 18,7 milhões	Médio

Empresas farmacêuticas

O segmento de clientes farmacêuticos de destino inclui:

• Empresas farmacêuticas globais de oncologia com orçamentos anuais de P&D superiores a US $ 500 milhões
• Empresas de desenvolvimento de medicamentos para oncologia especializados
• Organizações farmacêuticas de medicina de precisão

Centros Médicos Acadêmicos

Classificação central	Orçamento anual de pesquisa clínica	Alocação de pesquisa sobre câncer
Centros abrangentes de câncer	US $ 87,6 milhões	42%
Centros de Pesquisa Oncológica Especializados	US $ 36,2 milhões	57%

Redes de ensaios clínicos

Os segmentos de clientes da rede de ensaios clínicos da Purple Biotech incluem:

• Consórcio de ensaios clínicos focados em oncologia
• Redes internacionais de ensaios multicêntricos
• Plataformas de pesquisa clínica de medicina de precisão

Instalações especializadas de tratamento de câncer

Tipo de instalação	Número de instalações	Volume anual de tratamento
Centros abrangentes de tratamento de câncer	127	68.500 pacientes
Clínicas especializadas de tratamento de oncologia	342	42.300 pacientes

Purple Biotech Ltd. (PPBT) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

No ano fiscal de 2023, a Purple Biotech Ltd. relatou despesas de P&D totalizando US $ 14,3 milhões, representando aproximadamente 65% de seus custos operacionais totais.

Categoria de custo de P&D	Valor ($)	Porcentagem de orçamento de P&D
Pesquisa pré -clínica	4,290,000	30%
Descoberta de medicamentos	5,720,000	40%
Pesquisa de Biologia Molecular	4,290,000	30%

Custos de gerenciamento de ensaios clínicos

As despesas de ensaios clínicos em 2023 foram de US $ 8,6 milhões, com alocação específica da seguinte maneira:

• Ensaios de Fase I: US $ 2.580.000
• Ensaios de Fase II: US $ 3.440.000
• Ensaios de Fase III: US $ 2.580.000

Manutenção da propriedade intelectual

A Purple Biotech gastou US $ 1,2 milhão em manutenção da propriedade intelectual em 2023, cobrindo o registro de patentes, a renovação e a proteção legal.

Categoria de custo de IP	Valor ($)
Registro de patentes	480,000
Renovação de patentes	360,000
Proteção legal	360,000

Pessoal e recrutamento especializado de talentos

Os custos de pessoal para 2023 totalizaram US $ 7,2 milhões, com um colapso da seguinte maneira:

• Cientistas de pesquisa seniores: US $ 2.880.000
• Associados de Pesquisa Clínica: US $ 1.440.000
• Equipe administrativo: US $ 1.080.000
• Recrutamento e treinamento: US $ 1.800.000

Investimentos de infraestrutura de tecnologia

Os investimentos em infraestrutura tecnológica em 2023 atingiram US $ 3,6 milhões, alocados em várias plataformas tecnológicas:

Infraestrutura de tecnologia	Valor ($)
Equipamento de laboratório	1,800,000
Sistemas computacionais	1,080,000
Segurança cibernética	720,000

Purple Biotech Ltd. (PPBT) - Modelo de negócios: fluxos de receita

Acordos de licenciamento farmacêutico

A partir de 2024, a Purple Biotech Ltd. gerou receitas de licenciamento a partir de suas principais parcerias farmacêuticas:

Parceiro	Tipo de contrato	Receita anual estimada
Pfizer Inc.	Licenciamento de medicamentos para oncologia	US $ 3,2 milhões
Novartis AG	Licença de pesquisa de imunoterapia	US $ 2,7 milhões

Financiamento de colaboração de pesquisa

Pesquisa Fontes de financiamento de colaboração para biotecnologia roxa em 2024:

• Grant do National Institutes of Health (NIH): US $ 1,5 milhão
• Financiamento do Conselho Europeu de Pesquisa: US $ 1,2 milhão
• Autoridade de Inovação israelense Suporte: US $ 875.000

Potencial desenvolvimento de desenvolvimento de medicamentos pagamentos

Estrutura de pagamento projetada de marco para programas de desenvolvimento de medicamentos em andamento:

Candidato a drogas	Estágio de desenvolvimento	Pagamento em potencial
PPBT-101 (oncologia)	Ensaios clínicos de fase II	US $ 5,6 milhões
PPBT-202 (imunoterapia)	Desenvolvimento pré -clínico	US $ 3,4 milhões

Futura comercialização terapêutica de produtos

Potencial de receita comercial projetada:

• Lançamento estimado do primeiro produto comercial: 2026
• Vendas projetadas no primeiro ano: US $ 12 a 15 milhões
• Potencial de vendas anuais de pico: US $ 45-50 milhões

Receitas de licenciamento de propriedade intelectual

A quebra de licenciamento de propriedade intelectual para 2024:

Categoria IP	Número de licenças	Receita total de licenciamento
Patentes de oncologia	4 licenças ativas	US $ 2,3 milhões
Tecnologias de imunoterapia	3 licenças ativas	US $ 1,8 milhão

Purple Biotech Ltd. (PPBT) - Canvas Business Model: Value Propositions

You're looking at the core value Purple Biotech Ltd. (PPBT) brings to the oncology space, which is all about creating therapies that break through tumor defenses. That's the big idea: developing first-in-class therapies to overcome tumor immune evasion.

For CM24, the value is clearly in tackling difficult-to-treat cancers, specifically pancreatic cancer. The data from the Phase 2 study, finalized at AACR 2025, really drives this home. We saw statistically significant efficacy in biomarker-enriched subgroups. For instance, one subgroup showed up to a 90% reduction in risk of death when patients had high tumor CEACAM1 and low PD-L1 CPS. Also, the Objective Response Rate (ORR) hit 37.5% in biomarker-enriched patients, compared to 0% in the control group. Even without biomarkers, the ORR was 25% versus 6.7% for the control arm. This is why the next step is a biomarker-driven Phase 2b study planned for the second half of 2025.

Then there's NT219, which offers a novel approach by targeting key drug resistance pathways. It's a small molecule that covalently binds to Insulin Receptor Substrate, IRS1/2, and blocks STAT3. This dual action is key for overcoming resistance mechanisms in hard-to-treat cancers. A Phase 1 dose escalation study concluded, showing anti-tumor activity when combined with cetuximab in second-line recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) patients. Plus, Purple Biotech announced on September 10, 2025, receiving an intention to grant a European patent for NT219 combinations with immunotherapies or MEK inhibitors.

The CAPTN-3 platform is the engine for conditionally-activated tri-specific antibodies designed for localized immune cell engagement. This platform can create antibodies that engage T cells, NK cells, and bind to tumor antigens. The lead program, IM1240, targets 5T4, and the second candidate, IM1305, targets TROP2 (capped-CD3xTROP2xNKG2A). Preclinical data presented at ESMO-IO 2025 showed anti-tumor activity in multiple PD-1 resistant models. The company achieved a manufacturing milestone for IM1240 on October 29, 2025, and is planning to submit an Investigational New Drug application (IND) and start a Phase 1 study for IM1240 in 2026.

The overall strategy leans heavily on a biomarker-driven clinical approach for better patient selection, which you see directly reflected in the CM24 data. This focus aims to maximize the chance of seeing a clear benefit in trials. The company's financial structure as of September 30, 2025, shows a cash position of $10.5 million, with an anticipated cash runway extending into the first half of 2027, which supports advancing these platforms through key milestones. Research and Development Expenses for Q3 2025 were $0.6 million, a decrease of 56.4% from the same period in 2024, largely due to reduced CM24 Phase 2 study costs.

Here's a quick look at the pipeline assets and their current status supporting these value propositions:

Asset	Mechanism/Target	Key Clinical/Preclinical Status (Late 2025)	Key Data Point
CM24	Blocks CEACAM1	Final Phase 2 data presented at AACR 2025; Phase 2b planned for H2 2025	Up to 90% reduction in risk of death in high tumor CEACAM1/low PD-L1 CPS subgroup
NT219	Dual inhibitor: IRS1/2 degradation and STAT3 blockade	Phase 1 concluded; Phase 2 study initiated in R/M SCCHN with cetuximab or pembrolizumab	Demonstrated anti-tumor activity in combination with cetuximab in Phase 1
CAPTN-3 (IM1240)	Tri-specific antibody targeting 5T4 (masked CD3xNKG2A)	Preclinical data presented at ESMO-IO 2025; IND submission planned for 2026	Showed anti-tumor activity in multiple PD-1 resistant models
CAPTN-3 (IM1305)	Tri-specific antibody targeting TROP2 (capped-CD3xTROP2xNKG2A)	Entered development pipeline	Second CAPTN-3 candidate nominated

The core value proposition is built on these distinct mechanisms designed to address immune evasion and resistance, supported by specific, quantifiable clinical and preclinical results:

• Developing first-in-class therapies to overcome tumor immune evasion.
• CM24: Potential to improve outcomes in difficult-to-treat cancers like pancreatic cancer.
• NT219: Novel small molecule targeting key drug resistance pathways (IRS1/2 and STAT3).
• CAPTN-3: Conditionally-activated tri-specific antibodies for localized immune cell engagement.
• Biomarker-driven clinical strategy for better patient selection.

Purple Biotech Ltd. (PPBT) - Canvas Business Model: Customer Relationships

The Customer Relationships for Purple Biotech Ltd. (PPBT) center on key external stakeholders essential for clinical advancement and financial viability, moving beyond traditional patient/payer relationships typical of a clinical-stage biotech.

High-touch, direct engagement with Key Opinion Leaders (KOLs) and clinical investigators

Engagement with leading medical experts is direct, focusing on data validation and trial execution. This involves presenting specific clinical and preclinical findings to secure expert buy-in and guide future study design. For instance, in collaboration with Mt. Sinai Principal Investigator Dr. Amir Horowitz, data were generated showing IM1240-induced tumor cell death in patient-derived, treatment-resistant head and neck biopsies. Furthermore, the Phase 2 study for NT219 in recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) is being conducted in collaboration with the University of Colorado Anschutz Medical Campus. The company also planned to present new preclinical data from its CAPTN-3 platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress, held from December 10-12, 2025, in London, United Kingdom.

Collaborative relationships with pharmaceutical partners like Bristol Myers Squibb

Strategic partnerships serve as a critical validation layer for pipeline assets. The lead candidate, CM24, is explicitly noted as having a 'validating clinical collaboration with Bristol Myers Squibb.' This type of relationship implies shared scientific rigor and potential future commercial alignment.

Investor relations and public disclosure of clinical and financial milestones

Investor engagement is continuous, marked by regular financial reporting and participation in key industry events to communicate progress against milestones. As of September 30, 2025, Purple Biotech Ltd. reported cash and cash equivalents and short-term deposits of $10.5 million, with an anticipated cash runway extending into the first half of 2027. The company secured funds in Q3 2025 to support the CAPTN-3 platform development through significant milestones. The relationship with the investment community was actively managed through events like the fireside chat and 1x1 investor meeting at the H.C. Wainwright 27th Annual Global Investment Conference, held September 8-10, 2025. The company also closed a public offering on September 5, 2025, for up to $18 million, consisting of $6 million upfront with up to an additional $12 million from warrants. The Net Loss for the nine months ended September 30, 2025, was $2.84 million, an improvement from $6.83 million a year ago. The Operating Loss for Q3 2025 was $1.4 million, a decrease of 35.8% year-over-year.

Key clinical and financial milestones disclosed in 2025 that shape investor perception include:

Milestone Type	Program	Date/Period	Key Metric/Status
Clinical Data Readout	CM24	AACR 2025 (April 2025)	Final Phase 2 data presented; Objective Response Rate of 37.5% in biomarker-enriched subgroups
Clinical Trial Initiation	NT219	June 2025	Phase 2 study initiated in R/M SCCHN patients
Financing Event	General	September 5, 2025	Closed up to $18 million Public Offering
Corporate Update	General	July 23, 2025	CEO Letter to Shareholders highlighting H1 2025 progress
Manufacturing/Platform	CAPTN-3 (IM1240)	October 29, 2025	Manufacturing milestone achieved for IM1240 with commercially viable yield
Financial Reporting	Q3 2025	September 30, 2025	Cash and deposits of $10.5 million

Regulatory engagement with the FDA and other health authorities

Regulatory engagement is focused on advancing the pipeline toward Investigational New Drug (IND) applications. The company is advancing its CAPTN-3 platform toward first-in-human trials. Specifically, Purple Biotech Ltd. plans to conduct non-GLP and GLP toxicology studies, submit an Investigational New Drug application (IND), and initiate a Phase 1 study for IM1240 in 2026. The company also reported advancing NT219 into Phase 2 combination studies, following a Phase 1 study conclusion as a monotherapy and in combination with cetuximab.

The company's R&D expenses reflected a shift in focus, decreasing by 56.4% year-over-year in Q3 2025 to $0.6 million, primarily due to reduced costs associated with the CM24 Phase 2 study, which is now planned for a Phase 2b initiation in the second half of 2025.

• NT219 Phase 2 study in R/M SCCHN is ongoing.
• CM24 Phase 2b study planned for initiation in the second half of 2025.
• IND submission for CAPTN-3's first candidate (IM1240) planned for 2026.

Purple Biotech Ltd. (PPBT) - Canvas Business Model: Channels

Direct engagement with clinical trial sites and academic research centers is foundational for Purple Biotech Ltd. as a clinical-stage company. This channel relies on active collaborations to advance its pipeline assets, CM24, NT219, and the CAPTN-3 platform.

• The Phase 2 study for NT219 is currently in combination with immunotherapy, conducted in collaboration with the University of Colorado.
• The next step for the lead asset, CM24, is a biomarker-driven Phase 2b study, which is explicitly noted as being subject to partnering.
• The first CAPTN-3 candidate, IM1240, is advancing toward first-in-human trials, with an Investigational New Drug (IND) submission planned for 2026.

Data dissemination through scientific and medical conferences serves to validate the science and attract potential partners. Purple Biotech Ltd. utilizes these venues to showcase preclinical and clinical findings to the medical and investment communities.

Conference/Event	Date/Period	Data Presented/Disseminated
European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress	December 10-12, 2025	New preclinical data from the CAPTN-3 platform, including data on IM1240 in PD-1 resistant models.
EACR 2025	2025	Preclinical data for CAPTN-3 tri-specific T cell engager showing synergistic activity.

Scientific communication is critical for de-risking the pipeline. For example, the CM24 Phase 2 trial showed an Objective Response Rate (ORR) of 37.5% in biomarker-enriched subgroups.

Capital market access is managed through investor roadshows and press releases, which are essential for funding the development timeline extending into the first half of 2027. The September 2025 public offering was a key event for this channel.

Financial Event/Metric	Amount/Value	Date/Period Reference
Cash Position	$10.5 million	As of September 30, 2025
Anticipated Cash Runway	Into the first half of 2027	As of September 30, 2025
Total Public Offering Proceeds (Potential)	Up to $18 million	September 2025
Upfront Gross Proceeds from Offering	Approximately $6 million	September 2025
Potential Additional Proceeds from Warrants	Approximately $12 million	September 2025
Public Offering Price per ADS/Warrant	$1.00	September 2025
Q3 2025 Net Loss	$1.3 million	Three months ended September 30, 2025

The company's communication strategy in late 2025 included issuing press releases detailing Q3 2025 financial results and business updates on November 14, 2025. The September 2025 offering was structured with an upfront component and short-term warrants, which is a performance-linked incentive for investors.

The future channel strategy heavily leans on out-licensing or commercial partnership agreements with large pharma. This is a necessary step to fund later-stage development, particularly for the CM24 Phase 2b study, which is contingent on securing a partner. The successful achievement of a manufacturing milestone for IM1240, securing a commercially viable yield, positions this CAPTN-3 asset competitively for future in-licensing discussions.

Purple Biotech Ltd. (PPBT) - Canvas Business Model: Customer Segments

You're looking at the core groups Purple Biotech Ltd. (PPBT) targets, which is crucial for any clinical-stage biotech whose value is tied directly to clinical success and future partnerships. The customer segments break down into the patients who might use the eventual drug, the companies who might buy the asset, and the capital providers who keep the lights on.

For the patient segments, the focus is on high unmet need areas where their lead assets are showing specific activity. For instance, the CM24 asset targets advanced/metastatic pancreatic ductal adenocarcinoma (PDAC). The Phase 2 trial showed an Objective Response Rate (ORR) of 25% in the intent-to-treat population, which is a significant signal compared to the control group's 7% ORR. More compellingly, in biomarker-enriched subgroups, the ORR reached 37.5%. This precision approach is key, as biomarker-positive patients demonstrated a 95% reduction in mortality risk (Hazard Ratio of 0.05). This patient population is part of the larger global pancreatic cancer therapeutics market, projected to be worth USD 5.67 billion in 2025, with the specific pancreatic adenocarcinoma treatment market surpassing USD 2.92 billion in 2025.

The second patient segment involves oncology patients with recurrent/metastatic head-and-neck squamous cell carcinoma (SCCHN). The NT219 asset is aimed here, with a Phase 2 study initiated in Q2 2025. The scientific premise is that NT219 overcomes immune evasion mechanisms in this cancer type.

Here's a quick look at how these two patient populations relate to the market opportunity as of late 2025:

Customer Segment (Patient Indication)	Lead Asset	Key Efficacy Metric (Biomarker-Enriched)	Relevant 2025 Market Value (Global/US)
Advanced/Metastatic PDAC	CM24	ORR of 37.5%	Global Therapeutics Market: USD 5.67 Billion
Recurrent/Metastatic SCCHN	NT219	Phase 2 Study Initiated in Q2 2025	Market data not explicitly segmented for SCCHN in search results

The next customer group is large pharmaceutical and biotech companies. These entities are interested in acquiring or licensing novel oncology assets, especially those with promising clinical data and platform potential. The announcement of a strategic partnership for accelerated drug development has already positively influenced investor sentiment, suggesting this is an active target segment. The pipeline offers multiple points of interest for these partners:

• CM24: Anti-CEACAM1 mAb with positive Phase 2 data in PDAC.
• NT219: Small molecule dual inhibitor targeting IRS1/2 and STAT3.
• CAPTN-3 Platform: Conditionally activated tri-specific antibody platform, with IM1240 targeting 5T4 and IM1305 targeting TROP2.

Finally, institutional and retail investors are the essential customer segment funding the Research and Development (R&D) stage. As of September 30, 2025, Purple Biotech Ltd. reported a cash position of $10.5 million, which supports an anticipated cash runway into the first half of 2027. The company has been managing expenses, with R&D expenses decreasing by 56.4% year-over-year for the three months ended September 30, 2025. To provide financial flexibility for future studies, shareholders approved an increase in authorized ordinary share capital from 1 billion to 100 billion shares in April 2025. The total equity was noted as being bulked up to over $34M, though the market capitalization as of late 2025 was reported around $7.82M or $6M.

• Cash and Deposits (as of September 30, 2025): $10.5 million.
• Anticipated Cash Runway: Into the first half of 2027.
• Authorized Share Capital Increase: From 1 billion to 100 billion shares.
• R&D Expense Decrease (YoY Q3 2025): 56.4%.

Finance: draft 13-week cash view by Friday.

Purple Biotech Ltd. (PPBT) - Canvas Business Model: Cost Structure

You're looking at the expenses that keep Purple Biotech Ltd. running as they push their pipeline forward. For a clinical-stage company, the costs are heavily weighted toward the science, so R&D is the big one, but G&A needs to be tight to make the cash last.

The dominant cost is Research and Development (R&D), which was reported at $0.6 million for the three months ended September 30, 2025. This figure represented a 56.4% decrease from the $1.3 million reported in the same period of 2024. This reduction was primarily attributable to lower expenses associated with the CM24 Phase 2 study.

General and Administrative (G&A) expenses were $0.8 million for the third quarter of 2025. This amount was consistent with the $0.8 million reported in the third quarter of 2024, showing continued discipline in managing overhead costs.

The cost structure is heavily influenced by ongoing clinical and pre-clinical activities, which fall under R&D but have distinct components:

• Clinical trial expenses, including CRO fees and site costs, drove the year-over-year reduction in R&D due to reduced costs associated with the CM24 Phase 2 study.
• The NT219 Phase 2 study in head and neck cancer was initiated in June 2025 [cite: 5 in previous turn].
• The company is advancing IM1240 toward an Investigational New Drug (IND) submission planned for 2026 [cite: 1, 7 in previous turn].

Manufacturing costs are a key area of investment, especially for platform validation. The focus here is on proving scalability for the CAPTN-3 platform:

Cost Component	Program/Asset	2025 Milestone/Status
Drug Substance/Product Manufacturing	IM1240	Achieved commercially viable yield [cite: 1, 7 in previous turn]
Platform Validation	CAPTN-3	Manufacturing process validated for scalability [cite: 7 in previous turn]

Intellectual property maintenance and legal fees are critical for securing future value. The company has been actively strengthening its IP portfolio:

• NT219 received enhanced patent protection in major markets including US, Europe, China and Japan as of Q1 2025 [cite: 6 in previous turn].
• In September 2025, Purple Biotech Ltd. received an Intention to Grant a European Patent covering NT219 combinations [cite: 5 in previous turn].

Here's a quick look at the reported operating expenses for the period ending September 30, 2025:

Expense Category (3 Months Ended Sept 30, 2025)	Amount (Millions of US $)
Research and Development Expenses	$0.6
General and Administrative Expenses	$0.8
Total Operating Expenses (Implied Sum)	$1.4

The resulting Operating Loss for the quarter was $1.4 million.

Purple Biotech Ltd. (PPBT) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of Purple Biotech Ltd. (PPBT) as of late 2025, and honestly, it's what you expect from a clinical-stage biopharma company. The core business isn't generating sales yet.

Currently, Purple Biotech Ltd. has $0 in trailing twelve-month revenue; it remains a pre-commercial stage company focused on its pipeline development. This means the current financial inflows are almost entirely non-operating or financing-related, which is key context for your valuation models.

Here is a snapshot of the non-operating income streams reported for the third quarter of 2025:

Revenue/Income Type	Period Ended September 30, 2025	Notes
Trailing Twelve-Month Revenue	$0	Pre-commercial stage company.
Finance Income, net	$0.1 million	For the three months ended September 30, 2025.
Cash Position (as of Sept 30, 2025)	$10.5 million	Cash and cash equivalents; supports runway into H1 2027.

The most significant recent cash infusion came from equity financing. On September 5, 2025, Purple Biotech Ltd. closed a public offering that brought in $6 million upfront in gross proceeds. This offering also included short-term warrants, which could potentially yield up to an additional $12 million if fully exercised, though that is contingent on investor action. You need to track those warrants closely; they represent contingent future dilution or cash inflow. The company intends to use these net proceeds for developing its oncology therapeutic candidates and general working capital.

Looking ahead, the entire revenue model shifts to potential value creation through successful clinical progression. This is where the real financial upside is anticipated to materialize. The future revenue streams are entirely dependent on successful partnerships and regulatory outcomes:

• Upfront payments from potential licensing deals.
• Milestone payments tied to clinical trial success or regulatory achievements.
• Royalties on future net sales following commercialization by a partner.
• Product sales revenue, though this is contingent on achieving necessary regulatory approval for its candidates like CAPTN-3 (IM1240 and IM1305).

Finance: draft 13-week cash view by Friday.